This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—The attention of the Medical Research Council (Great Britain) has been drawn to a misleading advertisement, involving misuse of their name, which has been given currency on the American continent in respect of a preparation of ergotamine tartrate known as Gynergen "Sandoz." This advertisement states that "The Pharmaceutical Society of Great Britain, after consultation with the Medical Research Council, adopted Gynergen as the standard for ergot, thus making it the acknowledged leader in this field." This statement is not true.The Medical Research Council desire to make it plain that they never at any time concurred in, or were consulted about, the adoption of this preparation as a standard. The suggestion made with reference to the council is therefore entirely without foundation, and any statement implying their approval is a gross misrepresentation.Further, the current official publications of the Pharmaceutical Society of Great Britain state expressly that
Fletcher WM. GYNERGEN SANDOZ. JAMA. 1930;95(10):746. doi:10.1001/jama.1930.02720100044026